Sugi Predict

Sugi Predict / Compounds / SCHEMBL29935933

SCHEMBL29935933

SCHEMBL29935933

FC(F)(F)c1cccc2cccnc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSMD14 O00487 2/20 0.55
▸ COPS5 Q92905 2/20 0.55
▸ KDM4E B2RXH2 3/20 0.54
▸ CCR1 P32246 3/20 0.54
▸ CCR5 P51681 3/20 0.54
▸ CCR8 P51685 3/20 0.54
▸ MMP2 P08253 2/20 0.54
▸ TSHR P16473 2/20 0.54
▸ LMNA P02545 2/20 0.54
▸ MAPT P10636 2/20 0.54
▸ ALOX15 P16050 2/20 0.54
▸ HTT P42858 2/20 0.54
▸ GMNN O75496 1/20 0.54
▸ TP53 P04637 1/20 0.54
▸ HSP90AA1 P07900 1/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ CYP2D6 P10635 1/20 0.54
▸ MMP9 P14780 1/20 0.54
▸ NFKB1 P19838 1/20 0.54
▸ MMP8 P22894 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2569765 1.00 PSMD14 (0.55) PSMD14COPS5KDM4ECCR1CCR5
Quinoline SCHEMBL28226310 0.89 ALDH1A1 (0.57) PSMD14COPS5KDM4ECCR1CCR5
SCHEMBL18434789 0.83 SLC40A1 (0.51) PSMD14COPS5KDM4ECCR1CCR5
SCHEMBL762337 0.83 KDM4E (0.54) PSMD14COPS5KDM4ECCR1CCR5
SCHEMBL22016210 0.81 CCR1 (0.52) PSMD14COPS5KDM4ECCR1CCR5
SCHEMBL11850412 0.81 LMNA (0.47) PSMD14COPS5KDM4ECCR1CCR5
SCHEMBL20505776 0.80 KDM4E (0.50) PSMD14COPS5KDM4ECCR1CCR5
SCHEMBL3901211 0.80 LMNA (0.45) PSMD14COPS5KDM4ECCR1CCR5
SCHEMBL13301166 0.80 PSMD14 (0.62) PSMD14COPS5KDM4ECCR1CCR5
SCHEMBL31619478 0.79 PARP1 (0.45) KDM4EMMP2TSHRLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132109-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2026-05-14 — — US disclosed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 — — US disclosed
US-12503436-B2 Compounds and compositions for treating conditions associated with STING activity NOVARTIS PHARMA AG (CH) 2025-12-23 — — US disclosed
CN-120129683-A Azole derivatives as SHP2 inhibitors IRBM股份公司 2025-06-10 — — CN disclosed
CN-119139301-A Application of 2, 8-trifluoromethyl quinoline derivative in preventing and treating cow mastitis pathogenic bacteria 兰州大学 2024-12-17 — — CN disclosed
US-20240383876-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2024-11-21 — — US disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 — — US disclosed
EP-4198031-A1 TLR7/8 ANTAGONISTS AND USES THEREOF Merck Patent GmbH (DE) 2023-06-21 — — EP disclosed
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-06-01 — — US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 — — US disclosed
EP-4143194-A1 CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS GILEAD SCIENCES, INC. (US) 2023-03-08 — — EP disclosed
EP-3497094-B1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2023-02-15 — — EP disclosed
US-11512069-B2 TLR7/8 antagonists and uses thereof MERCK PATENT GMBH (DE) 2022-11-29 — — US disclosed
US-20220332713-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-20 — — US disclosed
CN-109563075-B TLR7/8 antagonists and uses thereof 默克专利股份公司 2022-09-30 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332713-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP PSMD14 3224/4885COPS5 3909/4885KDM4E 2437/4885
US-20260132109-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, IRF3, CGAS PSMD14 4250/4885COPS5 2429/4885KDM4E 4580/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH PSMD14 3735/4885COPS5 3505/4885KDM4E 3565/4885
US-20230145249-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP PSMD14 3224/4885COPS5 3909/4885KDM4E 2437/4885
US-12503436-B2 Compounds and compositions for treating conditions associated with STING activity STING1, CGAS, IRF3 PSMD14 3312/4885COPS5 2157/4885KDM4E 3761/4885
US-11512069-B2 TLR7/8 antagonists and uses thereof TLR7, TLR8, TLR9 PSMD14 3608/4885COPS5 2277/4885KDM4E 2390/4885
US-20240383876-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 PSMD14 3328/4885COPS5 2642/4885KDM4E 1839/4885
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 PSMD14 3312/4885COPS5 2157/4885KDM4E 3761/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP PSMD14 3224/4885COPS5 3909/4885KDM4E 2437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.